Date: 2018-08-03
Type of information: Development agreement
Compound: biomarkers associated with Oncologie’s Immuno-oncology pipeline
Company: HTG Molecular Diagnostics (USA - AZ) Oncologie (USA - MA)
Therapeutic area:
Type agreement: development
Action mechanism: biomarker
Disease:
Details:
- • On August 3, 2018, HTG Molecular Diagnostics, a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, an innovative biotechnology company with operations in Boston and Shanghai, announced the completion of a master agreement where the companies have agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline.
- Oncologie's current pipeline includes bavituximab, an investigational immune-modulatory monoclonal antibody that blocks activation by phosphatidylserine of TAM and TIM receptors on immune cells, and lefitolimod, an immunomodulator and toll-like receptor 9 (TLR-9) agonist.
Financial terms:
Latest news:
Is general: Yes
